FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891522150> ?p ?o ?g. }

• W2891522150 endingPage "62" @default.
• W2891522150 startingPage "57" @default.
• W2891522150 abstract "Patients with oligometastatic colorectal cancer have demonstrated excellent clinical outcomes with surgical resection of hepatic and pulmonary metastases. Stereotactic ablative radiation therapy (SABR) has emerged as an alternative local therapy for nonsurgical candidates. Herein, we report the oncologic and patient-reported quality-of-life (PR-QoL) outcomes for a subset of patients with oligometastatic colorectal cancer who were treated in a prospective phase 2 multicenter clinical trial.Patients with a pathologically proven diagnosis of oligometastatic colorectal cancer were enrolled as part of a prospective study. SABR dose and fractionation schedules were dependent on the lesion location and size. Patient follow-up occurred 6 weeks after completion of SABR and at 3-month intervals for the following 3 years. Patients received the Functional Assessment of Cancer Therapy-General questionnaire at baseline and at each follow-up visit to assess PR-QoL. The total Functional Assessment of Cancer Therapy-General questionnaire scores were compared with those from baseline using the Wilcoxon signed rank test. Overall survival, local progression-free survival (PFS), and distant PFS were calculated using the Kaplan-Meier estimation to the date of the last follow-up visit/death or local/distant failure.A total of 31 patients with oligometastatic colorectal cancer with 1 (71.0%), 2 (16.1%), 3 (3.2%), 4 (3.2%), or 5 (6.5%) metastatic lesions were identified. After a median follow-up time of 50.1 months, the median OS from the time of completion of the SABR was 53.9 months (95% confidence interval, 23.2-84.6), and the 5-year OS, local PFS, and distant PFS were 45%, 83%, and 27%, respectively. Acute grade 2+ toxicity was 9.7% (pain, nausea, fatigue) and late grade 3+ toxicity (small bowel obstruction) was 3.2% with no significant change in PR-QoL in the year after SABR.This subset analysis of a prospective phase 2 study demonstrates that SABR is a safe and effective treatment option for patients with unresectable oligometastic colorectal cancer. In addition, SABR of oligometastatic disease preserves PR-QoL." @default.
• W2891522150 created "2018-09-27" @default.
• W2891522150 creator A5008426497 @default.
• W2891522150 creator A5019661851 @default.
• W2891522150 creator A5019997274 @default.
• W2891522150 creator A5068231060 @default.
• W2891522150 creator A5069771417 @default.
• W2891522150 creator A5077226303 @default.
• W2891522150 creator A5082531572 @default.
• W2891522150 date "2019-01-01" @default.
• W2891522150 modified "2023-10-18" @default.
• W2891522150 title "Stereotactic Ablative Radiation Therapy for Unresectable Colorectal Oligometastases" @default.
• W2891522150 cites W2000208405 @default.
• W2891522150 cites W2007900522 @default.
• W2891522150 cites W2015107633 @default.
• W2891522150 cites W2024874898 @default.
• W2891522150 cites W2057741498 @default.
• W2891522150 cites W2059975503 @default.
• W2891522150 cites W2062633113 @default.
• W2891522150 cites W2070360377 @default.
• W2891522150 cites W2083128109 @default.
• W2891522150 cites W2099830092 @default.
• W2891522150 cites W2101815035 @default.
• W2891522150 cites W2115646671 @default.
• W2891522150 cites W2116353905 @default.
• W2891522150 cites W2146953097 @default.
• W2891522150 cites W2184776995 @default.
• W2891522150 cites W2285884723 @default.
• W2891522150 cites W2299946927 @default.
• W2891522150 cites W2473185806 @default.
• W2891522150 cites W2570618306 @default.
• W2891522150 cites W4237765593 @default.
• W2891522150 cites W4240340450 @default.
• W2891522150 cites W4362211014 @default.
• W2891522150 doi "https://doi.org/10.1016/j.adro.2018.09.001" @default.
• W2891522150 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6349603" @default.
• W2891522150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30706011" @default.
• W2891522150 hasPublicationYear "2019" @default.
• W2891522150 type Work @default.
• W2891522150 sameAs 2891522150 @default.
• W2891522150 citedByCount "8" @default.
• W2891522150 countsByYear W28915221502019 @default.
• W2891522150 countsByYear W28915221502020 @default.
• W2891522150 countsByYear W28915221502021 @default.
• W2891522150 countsByYear W28915221502022 @default.
• W2891522150 countsByYear W28915221502023 @default.
• W2891522150 crossrefType "journal-article" @default.
• W2891522150 hasAuthorship W2891522150A5008426497 @default.
• W2891522150 hasAuthorship W2891522150A5019661851 @default.
• W2891522150 hasAuthorship W2891522150A5019997274 @default.
• W2891522150 hasAuthorship W2891522150A5068231060 @default.
• W2891522150 hasAuthorship W2891522150A5069771417 @default.
• W2891522150 hasAuthorship W2891522150A5077226303 @default.
• W2891522150 hasAuthorship W2891522150A5082531572 @default.
• W2891522150 hasBestOaLocation W28915221501 @default.
• W2891522150 hasConcept C106159729 @default.
• W2891522150 hasConcept C121608353 @default.
• W2891522150 hasConcept C126322002 @default.
• W2891522150 hasConcept C141071460 @default.
• W2891522150 hasConcept C143998085 @default.
• W2891522150 hasConcept C159110408 @default.
• W2891522150 hasConcept C162324750 @default.
• W2891522150 hasConcept C187625094 @default.
• W2891522150 hasConcept C19617505 @default.
• W2891522150 hasConcept C2776256026 @default.
• W2891522150 hasConcept C2779951463 @default.
• W2891522150 hasConcept C2780387249 @default.
• W2891522150 hasConcept C44249647 @default.
• W2891522150 hasConcept C509974204 @default.
• W2891522150 hasConcept C526805850 @default.
• W2891522150 hasConcept C71924100 @default.
• W2891522150 hasConcept C85393063 @default.
• W2891522150 hasConcept C91602232 @default.
• W2891522150 hasConceptScore W2891522150C106159729 @default.
• W2891522150 hasConceptScore W2891522150C121608353 @default.
• W2891522150 hasConceptScore W2891522150C126322002 @default.
• W2891522150 hasConceptScore W2891522150C141071460 @default.
• W2891522150 hasConceptScore W2891522150C143998085 @default.
• W2891522150 hasConceptScore W2891522150C159110408 @default.
• W2891522150 hasConceptScore W2891522150C162324750 @default.
• W2891522150 hasConceptScore W2891522150C187625094 @default.
• W2891522150 hasConceptScore W2891522150C19617505 @default.
• W2891522150 hasConceptScore W2891522150C2776256026 @default.
• W2891522150 hasConceptScore W2891522150C2779951463 @default.
• W2891522150 hasConceptScore W2891522150C2780387249 @default.
• W2891522150 hasConceptScore W2891522150C44249647 @default.
• W2891522150 hasConceptScore W2891522150C509974204 @default.
• W2891522150 hasConceptScore W2891522150C526805850 @default.
• W2891522150 hasConceptScore W2891522150C71924100 @default.
• W2891522150 hasConceptScore W2891522150C85393063 @default.
• W2891522150 hasConceptScore W2891522150C91602232 @default.
• W2891522150 hasIssue "1" @default.
• W2891522150 hasLocation W28915221501 @default.
• W2891522150 hasLocation W28915221502 @default.
• W2891522150 hasLocation W28915221503 @default.
• W2891522150 hasLocation W28915221504 @default.
• W2891522150 hasOpenAccess W2891522150 @default.
• W2891522150 hasPrimaryLocation W28915221501 @default.

• next